Pharmacokinetic, Safety and Tolerability Study of SPARC1028
Evaluation of pharmacokinetic profile of SPARC1028
Solid Tumor in Advanced Stage
DRUG: SPARC1028
Determination of Maximum Tolerated Dose (MTD) during dose escalation, MTD for SPARC1028 will be determined as dose below the dose at which DLT (Dose Limiting Toxicity) is seen for ≥ 2 subjects, One 21-day treatment cycle
Establishing pharmacokinectic profile at each dose level for SPARC1028, Plasma levels of SPARC1028 will be determined and PK parameters viz., Cmax, AUC0-t, AUC0-∞, MRT, Tmax, t½, Kel, Vd, Cl for SPARC1028 will be evaluated, One 21-day treatment cycle
This is a phase I study of SPARC1028 and recommend phase II dose of SPARC1028 administered once a week for 3 weeks, followed by 1 week of rest.